These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 35098571)

  • 1. Erratum for Nevi, et al. DCLK1, a putative stem cell marker in human cholangiocarcinoma.
    Hepatology; 2022 Mar; 75(3):773. PubMed ID: 35098571
    [No Abstract]   [Full Text] [Related]  

  • 2. DCLK1, a Putative Stem Cell Marker in Human Cholangiocarcinoma.
    Nevi L; Di Matteo S; Carpino G; Zizzari IG; Samira S; Ambrosino V; Costantini D; Overi D; Giancotti A; Monti M; Bosco D; De Peppo V; Oddi A; De Rose AM; Melandro F; Bragazzi MC; Faccioli J; Massironi S; Grazi GL; Panici PB; Berloco PB; Giuliante F; Cardinale V; Invernizzi P; Caretti G; Gaudio E; Alvaro D
    Hepatology; 2021 Jan; 73(1):144-159. PubMed ID: 32978808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High expression of the putative cancer stem cell marker, DCLK1, in rectal neuroendocrine tumors.
    Ikezono YU; Koga H; Abe M; Akiba J; Kawahara A; Yoshida T; Nakamura T; Iwamoto H; Yano H; Kage M; Sata M; Tsuruta O; Torimura T
    Oncol Lett; 2015 Oct; 10(4):2015-2020. PubMed ID: 26622789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased expression of DCLK1, a novel putative CSC maker, is associated with tumor aggressiveness and worse disease-specific survival in patients with bladder carcinomas.
    Shafiei S; Kalantari E; Saeednejad Zanjani L; Abolhasani M; Asadi Lari MH; Madjd Z
    Exp Mol Pathol; 2019 Jun; 108():164-172. PubMed ID: 31028726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Doublecortin-like kinase 1 exhibits cancer stem cell-like characteristics in a human colon cancer cell line.
    Li L; Bellows CF
    Chin J Cancer Res; 2013 Apr; 25(2):134-42. PubMed ID: 23592893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DCLK1, a promising colorectal cancer stem cell marker, regulates tumor progression and invasion through miR-137 and miR-15a dependent manner.
    Razi S; Sadeghi A; Asadi-Lari Z; Tam KJ; Kalantari E; Madjd Z
    Clin Exp Med; 2021 Feb; 21(1):139-147. PubMed ID: 32965580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Cell Production of Interleukin 17 Induces Stem Cell Features of Pancreatic Intraepithelial Neoplasia Cells.
    Zhang Y; Zoltan M; Riquelme E; Xu H; Sahin I; Castro-Pando S; Montiel MF; Chang K; Jiang Z; Ling J; Gupta S; Horne W; Pruski M; Wang H; Sun SC; Lozano G; Chiao P; Maitra A; Leach SD; Kolls JK; Vilar E; Wang TC; Bailey JM; McAllister F
    Gastroenterology; 2018 Jul; 155(1):210-223.e3. PubMed ID: 29604293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tuft and Cancer Stem Cell Marker DCLK1: A New Target to Enhance Anti-Tumor Immunity in the Tumor Microenvironment.
    Cao Z; Weygant N; Chandrakesan P; Houchen CW; Peng J; Qu D
    Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33348546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic Neuroendocrine Tumors and EMT Behavior Are Driven by the CSC Marker DCLK1.
    Ikezono Y; Koga H; Akiba J; Abe M; Yoshida T; Wada F; Nakamura T; Iwamoto H; Masuda A; Sakaue T; Yano H; Tsuruta O; Torimura T
    Mol Cancer Res; 2017 Jun; 15(6):744-752. PubMed ID: 28179411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of cancer stem-cell marker doublecortin-like kinase 1 in head and neck squamous cell carcinoma.
    Kadletz L; Thurnher D; Wiebringhaus R; Erovic BM; Kotowski U; Schneider S; Schmid R; Kenner L; Heiduschka G
    Oral Oncol; 2017 Apr; 67():109-118. PubMed ID: 28351564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the cancer stem cell marker DCLK1 in patients with lymph node metastases of head and neck cancer.
    Kadletz L; Kenner L; Wiebringhaus R; Jank B; Mayer C; Gurnhofer E; Konrad S; Heiduschka G
    Pathol Res Pract; 2019 Dec; 215(12):152698. PubMed ID: 31706685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DCLK1 is detectable in plasma of patients with Barrett's esophagus and esophageal adenocarcinoma.
    Whorton J; Sureban SM; May R; Qu D; Lightfoot SA; Madhoun M; Johnson M; Tierney WM; Maple JT; Vega KJ; Houchen CW
    Dig Dis Sci; 2015 Feb; 60(2):509-13. PubMed ID: 25283374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Doublecortin-like kinase 1 is elevated serologically in pancreatic ductal adenocarcinoma and widely expressed on circulating tumor cells.
    Qu D; Johnson J; Chandrakesan P; Weygant N; May R; Aiello N; Rhim A; Zhao L; Zheng W; Lightfoot S; Pant S; Irvan J; Postier R; Hocker J; Hanas JS; Ali N; Sureban SM; An G; Schlosser MJ; Stanger B; Houchen CW
    PLoS One; 2015; 10(2):e0118933. PubMed ID: 25723399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammatory and oncogenic roles of a tumor stem cell marker doublecortin-like kinase (DCLK1) in virus-induced chronic liver diseases.
    Ali N; Chandrakesan P; Nguyen CB; Husain S; Gillaspy AF; Huycke M; Berry WL; May R; Qu D; Weygant N; Sureban SM; Bronze MS; Dhanasekaran DN; Houchen CW
    Oncotarget; 2015 Aug; 6(24):20327-44. PubMed ID: 25948779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The recently suggested intestinal cancer stem cell marker DCLK1 is an epigenetic biomarker for colorectal cancer.
    Vedeld HM; Skotheim RI; Lothe RA; Lind GE
    Epigenetics; 2014 Mar; 9(3):346-50. PubMed ID: 24384857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upregulation of circulating cancer stem cell marker, DCLK1 but not Lgr5, in chemoradiotherapy-treated colorectal cancer patients.
    Mirzaei A; Tavoosidana G; Modarressi MH; Rad AA; Fazeli MS; Shirkoohi R; Tavakoli-Yaraki M; Madjd Z
    Tumour Biol; 2015 Jun; 36(6):4801-10. PubMed ID: 25631749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer.
    Ge Y; Weygant N; Qu D; May R; Berry WL; Yao J; Chandrakesan P; Zheng W; Zhao L; Zhao KL; Drake M; Vega KJ; Bronze MS; Tomasek JJ; An G; Houchen CW
    Int J Cancer; 2018 Sep; 143(5):1162-1175. PubMed ID: 29577277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DCLK1 immunoreactivity in colorectal neoplasia.
    Gagliardi G; Goswami M; Passera R; Bellows CF
    Clin Exp Gastroenterol; 2012; 5():35-42. PubMed ID: 22557932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the clinical significance of DCLK1
    Dai T; Hu Y; Lv F; Ozawa T; Sun X; Huang J; Han X; Kishi H; Muraguchi A; Jin A
    Onco Targets Ther; 2018; 11():5047-5057. PubMed ID: 30174443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional implication of Dclk1 and Dclk1-expressing cells in cancer.
    Westphalen CB; Quante M; Wang TC
    Small GTPases; 2017 Jul; 8(3):164-171. PubMed ID: 27458755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.